- Home
- OSTX vs OPTN Comparison
OSTX vs OPTN Comparison
Compare OSTX & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- OPTN
- Stock Information
- Founded
- OSTX 2018
- OPTN 2010
- Country
- OSTX United States
- OPTN United States
- Employees
- OSTX N/A
- OPTN N/A
- Industry
- OSTX
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- OPTN Health Care
- Exchange
- OSTX NYSE
- OPTN Nasdaq
- Market Cap
- OSTX 86.5M
- OPTN 99.7M
- IPO Year
- OSTX 2024
- OPTN 2017
- Fundamental
- Price
- OSTX $2.25
- OPTN $0.44
- Analyst Decision
- OSTX Strong Buy
- OPTN Strong Buy
- Analyst Count
- OSTX 1
- OPTN 3
- Target Price
- OSTX $21.00
- OPTN $3.00
- AVG Volume (30 Days)
- OSTX 19.7K
- OPTN 658.7K
- Earning Date
- OSTX 11-26-2024
- OPTN 11-12-2024
- Dividend Yield
- OSTX N/A
- OPTN N/A
- EPS Growth
- OSTX N/A
- OPTN N/A
- EPS
- OSTX N/A
- OPTN N/A
- Revenue
- OSTX N/A
- OPTN $75,672,000.00
- Revenue This Year
- OSTX N/A
- OPTN $24.44
- Revenue Next Year
- OSTX $9,900.00
- OPTN $49.00
- P/E Ratio
- OSTX N/A
- OPTN N/A
- Revenue Growth
- OSTX N/A
- OPTN 5.13
- 52 Week Low
- OSTX $2.10
- OPTN $0.41
- 52 Week High
- OSTX $4.90
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- OPTN 24.21
- Support Level
- OSTX N/A
- OPTN $0.66
- Resistance Level
- OSTX N/A
- OPTN $0.81
- Average True Range (ATR)
- OSTX 0.00
- OPTN 0.06
- MACD
- OSTX 0.00
- OPTN -0.03
- Stochastic Oscillator
- OSTX 0.00
- OPTN 5.68
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.